Even the combination of the five genes, including LARP4B, PLEKHF2, SMC4, SLC45A3 and NO6632,39,44,45,48,51, whose clinical relevance and prognostic implications were observed in prostate cancer, had very limited prediction strength for BCR and RFS (not reported in the Results section). This evidence concerns the gene PLEKHF2 and Familial prostate cancer.